Enriched Tear Film (ETFTM) Gene Therapy in Action
Harnessing the body’s natural mechanism to heal the ocular surface, Oyster Point has pioneered a novel approach to potentially treat diseases of the ocular surface. ETFTM Gene Therapy is an adeno-associated virus (AAV)-based approach where, via intralacrimal gland injection, the lacrimal gland cells are provided a genetic message that may change cell behavior and function on the ocular surface. The genetic message may direct the production of selected antibodies, hormones, peptides, enzymes or cytokines that are secreted into the lacrimal ﬂuid and ultimately combine with the tear ﬁlm on the ocular surface. Our initial gene therapy targets are focused on chronic diseases of the ocular surface using selected, naturally occurring human proteins, peptides, or enzymes.
In diseases of the ocular surface where there is inadequate tear ﬁlm production, or where increased amounts of selected gene product are needed, secretion of the selected gene product may be modulated with administration of OC-01 (varenicline) nasal spray, which has been shown in preclinical and clinical models to increase tear ﬁlm production.